Health care resource utilization endpoints in phase 2/3 trials can indicate additional benefits to patients and provide supplementary evidence for registration. For example, reduced physician visits or less time in hospital can translate into large economic advantages over existing treatments. Health care resource use data that is collected during a clinical trial is often simply summarized in the clinical study report (CSR) and may be overlooked. Our team of statisticians and health economists help determine the costs and benefits of new treatments by applying unit costing to clinical trial data.
